Biovox develops bioplastic compounds that offer features such as inherent antimicrobial properties. At the same time, they are environmentally friendly.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International
SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.
This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.
The European Association of Chemical Distributors (FECC) invites you to embark on a 3-day journey, encompassing unique insights from major value-chain players in combination with lots of facts & figures, ample networking opportunities plus entertainment.
The World Adhesives Conference, taking place only every four years, is the most important event for all stakeholders involved in the adhesive and sealant sector and attracts well over a thousand delegates from all continents. The visitors are adhesive and sealant producers, raw
material suppliers, service providers, scientists and downstream
users.
CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
